Agios Pharmaceuticals | AGIO - Loan Capital


Agios Pharmaceuticals reported $1.06M in Loan Capital for its fiscal quarter ending in September of 2022.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
Astellas Pharma JPY 320B 0 Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
Bayer EUR 30.68B 1.15B Mar/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Daiichi Sankyo JPY 500B 199.92B Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Moderna USD 597M 6M Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Novartis USD 37.49B 42M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.5B 70M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025